Jun
11
2011

Insmed’s ARIKACE

Originally posted in Cystic Fibrosis News From Medical News Today

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, announced positive data through six treatment cycles (72 weeks total duration) of its Phase 2 clinical trial program for ARIKACE

Written by Cystic Fibrosis News From Medical News Today in: Cystic Fibrosis |

No Comments »

RSS feed for comments on this post. TrackBack URL

Leave a Reply

You must be logged in to post a comment.

Bookmark Us!

©Uncle & Drunken Crayfish Productions 2011 www.DrunkenCrayfish.com DrunkenCrayfish

Visit our NEW site at PocketBiker.com
PocketBiker.com Logo

 

TheBuckmaker.com Wordpress Themes | Hosting Provider, Mixed-Tape Free Music